Thermo Fisher Expands Biologics Toolkit with CHO-K1 Media Panel…

Event summary

Thermo Fisher launched the Gibco™ CHO-K1 Catalog Panel on September 23, 2026, offering cGMP-ready basal and feed media for CHO-K1 cell lines.
The panel demonstrated up to 73% higher titer and 202% higher peak viable cell density in a 14-day fed-batch study.
Available in liquid and dry powder formats, the panel supports process development, scale-up, and manufacturing.
The chemically defined, animal origin-free formulations are designed for regulatory compliance.

The big picture

Thermo Fisher's launch targets the growing demand for scalable, high-performance solutions in biologics manufacturing. The panel aligns with industry trends toward chemically defined media and regulatory-ready processes, as CHO-K1 cell lines remain the backbone of therapeutic protein production. With annual revenue exceeding $45 billion, Thermo Fisher leverages its global supply chain to position this as a standard tool for biologic developers.

What we're watching

Adoption Pace: How quickly biologic developers will integrate the panel into their workflows, given its performance claims.
Competitive Response: Whether rivals like Merck or Lonza will accelerate their own CHO-K1 media offerings.
Regulatory Impact: The extent to which cGMP-ready formulations will streamline approvals for biologics using this panel.